ARCUTIS BIOTHERAPEUTICS, INC. Accounts Payable
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) had Accounts Payable of $6.60 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-05
- 2026-06-30: Accounts Payable, Current $6.60M.
- 2026-03-31: Accounts Payable, Current $18.30M.
- 2025-12-31: Accounts Payable, Current $12.53M.
- 2025-09-30: Accounts Payable, Current $5.79M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $6.60M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $18.30M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $12.53M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $5.79M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $15.08M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $24.53M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $14.22M 10-K · filed 2026-02-25 |
| 2024-09-30 | $19.32M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $7.94M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $12.97M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $11.99M 10-K · filed 2025-02-25 |
| 2023-09-30 | $13.18M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $17.16M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $12.48M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $8.83M 10-K · filed 2024-02-27 |
| 2022-09-30 | $8.67M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $8.44M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $12.47M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $7.35M 10-K · filed 2023-02-28 |
| 2021-09-30 | $4.87M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $2.68M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $3.15M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $7.14M 10-K · filed 2022-02-22 |
| 2020-09-30 | $5.04M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $8.25M 10-Q · filed 2020-08-11 |
| 2020-03-31 | $4.76M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $1.41M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |